ClinicalTrials.gg
Not yet recruitingNCT07779083Updated Aug 21, 2026

Virtual Reality (VR) Audiovisual Distraction to Reduce Pain and Anxiety for Prone Pain Procedures

An interventional study of Virtual Reality (VR) Audiovisual Distraction in Procedural Pain and Procedural Anxiety, sponsored by University of California, Davis. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by University of California, Davis · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates whether virtual reality (VR) audiovisual distraction can reduce pain, anxiety, and the need for pain and anxiety medications during prone pain procedures, compared to standard care alone. The trial design is a two-arm, parallel assignment, randomized controlled trial at a single site, the UC Davis Pain Medicine Clinic. Patients will be randomized in a 1:1 allocation to the intervention (commercially available virtual reality headset (Meta Quest 3) with audiovisual calming nature scene and an ergonomic cushion/support) vs control (standard medical care). The primary outcome will be a composite outcome analyzed using the Win Ratio method comparing opioid/sedative medication use, intra-procedural pain scores, and intra-procedural anxiety scores between groups. Approximately 230 people at UC Davis are expected to participate (Up to 20 patients for the preliminary run-in period to acclimatize research and clinical staff and 210 total for the randomized clinical trial). Each participant's involvement consists of one visit, estimated at 30 minutes.

02

Conditions studied

  • Procedural Pain
  • Procedural Anxiety

Keywords

  • Virtual Reality
  • Pain
  • Anxiety
  • Prone Pain Procedure
  • Audiovisual Distraction
03

In context

Pain, Procedural

241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.

This study's planned enrollment of 230 is above the median of 90 across 227 interventional studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

University of California, Davis is the lead sponsor of 809 studies on the registry; 142 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 43 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years old or older
  • Male and female gender
  • Referred to UC Davis Pain Medicine Clinic and require a prone pain procedure
  • English speaking and with the ability to understand oral and written instructions

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Prisoners
  • Patients who have high risk of motion sickness
  • Seizure disorder
  • Visual/hearing impairment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Virtual Reality (VR) Audiovisual Distraction

    Participants received a commercially available virtual reality headset (Meta Quest 3) with audiovisual calming nature scene and an ergonomic cushion/support in addition to standard medical care based on the independent treating physician.

    Behavioral: Virtual Reality (VR) Audiovisual Distraction

  • No intervention
    Standard Care

    Standard medical care based on the independent treating physician, which includes standard care such as numbing and sedating medicines without audiovisual distraction.

Interventions

  • BehavioralVirtual Reality (VR) Audiovisual Distraction

    Using a VR headset with an ergonomic cushion/support which will display a calming audiovisual experience during the procedure. The VR headset is a commercially available Meta Quest 3.

06

What researchers measure

Primary outcomes

  1. Composite Outcome Using Win Ratio Method (Opioid/Sedative Use, Intra-procedural Pain Score, and Intra-procedural Anxiety Score)

    The primary outcome is a composite analyzed using the Win Ratio method. Each intervention patient will be compared with each control patient. Pairs are evaluated in priority order: opioid/sedative use, intra-procedural pain score, then intra-procedural anxiety score. A patient who received no opioids/sedatives wins over one who did; if tied, the lower pain score wins; if still tied, the lower anxiety score wins. If all three measures are identical, the pair is a tie. The Win Ratio is calculated as total intervention wins divided by total control wins. A Win Ratio \>1 indicates superiority of VR; a 95% confidence interval will be calculated. Pain and anxiety are measured using the Numeric Rating Scale (NRS), from 0 (none) to 10 (worst possible), with higher scores indicating worse outcomes.

    Time frame: During the procedure, approximately 30 minutes

Secondary outcomes

  1. Opioid and Sedative Medication Use

    Whether opioid and/or sedative medications were administered during the prone pain procedure.

    Time frame: During the procedure, approximately 30 minutes

  2. Intra-procedural Pain Score on the Numeric Rating Scale (NRS)

    Pain assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no pain) to 10 (worst possible pain). Higher scores indicate a worse outcome.

    Time frame: During the procedure, approximately 30 minutes

  3. Intra-procedural Anxiety Score on the Numeric Rating Scale (NRS)

    Anxiety assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no anxiety) to 10 (worst possible anxiety). Higher scores indicate a worse outcome.

    Time frame: During the procedure, approximately 30 minutes

  4. Pain Intensity on the Patient-Reported Outcomes Measurement Information System Pain Intensity Short Form-3a (PROMIS Pain Intensity SF-3a)

    PROMIS Pain Intensity Short Form-3a. Scores range from 3 to 15. Higher scores indicate a worse outcome.

    Time frame: Pre-procedure and post-procedure, approximately 30 minutes

  5. Anxiety on the State-Trait Anxiety Inventory 6-item (STAI-6)

    State-Trait Anxiety Inventory 6-item (STAI-6). Scores range from 4 to 24. Higher scores indicate a worse outcome.

    Time frame: Pre-procedure and post-procedure, approximately 30 minutes

  6. Patient Global Impression of Change (PGIC)

    Patient Global Impression of Change. Scores range from 1 to 7. Higher scores indicate a better outcome.

    Time frame: Post-procedure, approximately 30 minutes

  7. Patient Experience Satisfaction

    Patient Experience Satisfaction. Scores range from 0 to 10. Higher scores indicate a better outcome.

    Time frame: Post-procedure, approximately 30 minutes

  8. Virtual Reality Experience Feedback

    Virtual Reality experience feedback (immersion, comfort, side effects, usability, task load). No score range or directionality as it is a free response section.

    Time frame: Post-procedure, approximately 30 minutes

07

Study locations

1 site
  • UC Davis Pain Clinic
    Sacramento, California 95817, United States
    • Michael J. Jung, MD, MBA · Contactmijjung@health.ucdavis.edu · 916-734-6824
    • Michael J. Jung, MD, MBA · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07779083
Responsible party
Michael Jihnouk Jung (Associate Professor of Clinical Anesthesiology and Pain Medicine, University of California, Davis) — Principal investigator
First posted
Aug 21, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

Michael J. Jung, MD, MBA
Contact
mijjung@health.ucdavis.edu
916-734-6824
Michael J. Jung, MD, MBA
principal investigator · University of California, Davis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion